Dear Mr. Rodman, Ms. Diakov, Representative Moser, Mr. Peavler, and Mr. Jones:
My name is Dr. Stephen Taylor, and I am the President of the American Society of Addiction Medicine (ASAM). I am also board-certified in addiction medicine, addiction psychiatry, child and adolescent psychiatry, and general psychiatry.
First, let me thank KBML for deferring consideration of its currently proposed regulation on buprenorphine.
Attached for your review is a joint statement prepared by leading national and state medical organizations on KBML’s proposed buprenorphine regulation. This statement was originally intended for submission to the Administrative Regulation Review Subcommittee (the “Subcommittee”), urging the Subcommittee to find KBML’s proposed 201 KAR 9:270 deficient and to recommend either its amendment to address the identified issues or its repeal in full.
In light of KBML’s proactive decision to defer the proposal, I am sharing this statement directly with KBML and those on this email in the hope that the noted deficiencies may be addressed in a timely and constructive manner.
On behalf of ASAM, please know that we stand ready to provide technical assistance and support as needed.
Thank you in advance for your consideration.
Kindest Regards,
Stephen M. Taylor, MD
Stephen M. Taylor, MD, MPH, DFAPA, DFASAM
General, Child & Adolescent, Addiction and Sports Psychiatrist;
Diplomate of the American Board of Psychiatry and Neurology and
The American Board of Preventive Medicine
Chief Medical Officer, Pathway Healthcare Services, LLC;
President, American Society of Addiction Medicine (ASAM)
Chair, ASAM Delegation to the AMA House of Delegates
2100 Hickory Ridge Circle
Vestavia, AL 35243-2925
Phone: 205-790-2155
Email: staylor@smtmd.com or